
Thomas Horvatits

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7507548/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hepatitis E, Schistosomiasis and Echinococcosis–Prevalence in a Cohort of Pregnant Migrants in Germany and Their Influence on Fetal Growth Restriction. Pathogens, 2022, 11, 58.	2.8	0
2	Lack of Evidence for an Association between Previous HEV Genotype-3 Exposure and Glomerulonephritis in General. Pathogens, 2022, 11, 18.	2.8	4
3	Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial. Trials, 2022, 23, 302.	1.6	5
4	Microplastics detected in cirrhotic liver tissue. EBioMedicine, 2022, 82, 104147.	6.1	124
5	Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and metaâ€analysis. Liver International, 2021, 41, 449-455.	3.9	16
6	Lower Levels of Transaminases but Higher Levels of Serum Creatinine in Patients with Acute Hepatitis E in Comparison to Patients with Hepatitis A. Pathogens, 2021, 10, 60.	2.8	11
7	Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era. Scandinavian Journal of Gastroenterology, 2021, 56, 840-848.	1.5	2
8	HEV-Associated Neuralgic Amyotrophy: A Multicentric Case Series. Pathogens, 2021, 10, 672.	2.8	1
9	Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. International Journal of Obesity, 2021, 45, 2197-2204.	3.4	21
10	Hepatitis E virus persists in the ejaculate of chronically infected men. Journal of Hepatology, 2021, 75, 55-63.	3.7	17
11	Hepatitis E. , 2021, , 329-335.		0
12	Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or survival. Annals of Hepatology, 2021, 26, 100559.	1.5	4
13	Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic. PLoS ONE, 2021, 16, e0258450.	2.5	1
14	No link between male infertility and HEV genotype 3 infection. Gut, 2020, 69, 1150-1151.	12.1	12
15	Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. Clinical Infectious Diseases, 2020, 71, 1204-1211.	5.8	74
16	Significance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection. Pathogens, 2020, 9, 755.	2.8	7
17	Monocytes as Potential Mediators of Pathogenâ€Induced Tâ€Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC). Hepatology, 2020, 72, 1310-1326.	7.3	50
18	The Clinical Perspective on Hepatitis E. Viruses, 2019, 11, 617.	3.3	85

THOMAS HORVATITS

#	Article	IF	CITATIONS
19	Comparison of the integrin $\hat{I}\pm4\hat{I}^2$ 7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis. PLoS ONE, 2019, 14, e0220008.	2.5	16
20	SAT-208-Zinc/Ribavirin: A possible treatment option in chronically HEV genotype 3 infected patients without SVR under ribavirin monotherapy. Journal of Hepatology, 2019, 70, e721-e722.	3.7	2
21	Liver Injury and Failure in Critical Illness. Hepatology, 2019, 70, 2204-2215.	7.3	88
22	Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival. JHEP Reports, 2019, 1, 90-98.	4.9	30
23	Hypoxic liver injury after in- and out-of-hospital cardiac arrest: Risk factors and neurological outcome. Resuscitation, 2019, 137, 175-182.	3.0	19
24	<scp>HEV</scp> in pregnancy: Understanding the crucial role of steroid hormones. Liver International, 2019, 39, 621-622.	3.9	5
25	Hepatitis E seroprevalence in the Americas: A systematic review and metaâ€analysis. Liver International, 2018, 38, 1951-1964.	3.9	44
26	Outcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation. United European Gastroenterology Journal, 2018, 6, 104-111.	3.8	19
27	Acid–base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. Annals of Intensive Care, 2018, 8, 48.	4.6	24
28	Lack of evidence for human serum albumin as major source of HEV infections. Transfusion Medicine, 2018, 28, 470-471.	1.1	2
29	HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients. Journal of Hepatology, 2018, 69, 36-42.	3.7	80
30	Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in miceâ€. Hepatology, 2018, 68, 634-651.	7.3	39
31	Response for letter "Be cautious in comparing the seroprevalence of hepatitis E detected at different years in different countriesâ€: Liver International, 2018, 38, 2341-2341.	3.9	1
32	Extrahepatic manifestations and HEV, the genotype matters. EBioMedicine, 2018, 36, 3-4.	6.1	8
33	Course of HEV viremia and anti-HEV IgM/IgG response in asymptomatic blood donors. Journal of Clinical Virology, 2018, 105, 26-30.	3.1	23
34	Renal replacement therapy in critically ill liver cirrhotic patients—outcome and clinical implications. Liver International, 2017, 37, 843-850.	3.9	55
35	Circulating bile acids predict outcome in critically ill patients. Annals of Intensive Care, 2017, 7, 48.	4.6	49
36	Serum bile acids in patients with hepatopulmonary syndrome. Zeitschrift Fur Gastroenterologie, 2017, 55, 361-367.	0.5	9

THOMAS HORVATITS

#	Article	IF	CITATIONS
37	Serum bile acids as marker for acute decompensation and acuteâ€onâ€chronic liver failure in patients with nonâ€cholestatic cirrhosis. Liver International, 2017, 37, 224-231.	3.9	47
38	Outcome of in- and out-of-hospital cardiac arrest survivors with liver cirrhosis. Annals of Intensive Care, 2017, 7, 103.	4.6	21
39	Coagulation parameters and major bleeding in critically ill patients with cirrhosis. Hepatology, 2016, 64, 556-568.	7.3	148
40	Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit. Annals of Intensive Care, 2016, 6, 61.	4.6	28
41	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. Digestive and Liver Disease, 2016, 48, 1194-1199.	0.9	1
42	Prognostic impact of ICG-PDR in patients with hypoxic hepatitis. Annals of Intensive Care, 2015, 5, 47.	4.6	14
43	Gender-specific differences in energy metabolism during the initial phase of critical illness. European Journal of Clinical Nutrition, 2014, 68, 707-711.	2.9	28
44	Therapeutic options in pulmonary hepatic vascular diseases. Expert Review of Clinical Pharmacology, 2014, 7, 31-42.	3.1	16
45	Pharmacokinetics of Ganciclovir during Continuous Venovenous Hemodiafiltration in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 94-101.	3.2	20
46	Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. Journal of Hepatology, 2014, 60, 1187-1193.	3.7	28
47	von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. Journal of Hepatology, 2014, 61, 544-549.	3.7	43
48	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. Journal of Hepatology, 2014, 60, 1135-1142.	3.7	39
49	Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. Intensive Care Medicine, 2013, 39, 1227-1237.	8.2	46
50	Hypoxic liver injury and cholestasis in critically ill patients. Current Opinion in Critical Care, 2013, 19, 128-132.	3.2	75